Wedbush Reiterates “Outperform” Rating for Achaogen Inc (AKAO)
Wedbush restated their outperform rating on shares of Achaogen Inc (NASDAQ:AKAO) in a research report sent to investors on Wednesday morning. They currently have a $28.00 target price on the biopharmaceutical company’s stock.
A number of other equities analysts also recently issued reports on AKAO. Needham & Company LLC reiterated a buy rating and set a $29.00 price target on shares of Achaogen in a research report on Wednesday, March 15th. Zacks Investment Research downgraded Achaogen from a buy rating to a hold rating in a research report on Wednesday, March 8th. Stifel Nicolaus increased their price target on Achaogen from $27.00 to $28.00 and gave the stock a buy rating in a research report on Wednesday, March 15th. Aegis increased their price target on Achaogen from $20.00 to $29.00 and gave the stock a buy rating in a research report on Thursday, February 23rd. Finally, Cowen and Company reiterated a buy rating on shares of Achaogen in a research report on Tuesday, December 13th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $25.98.
Achaogen (NASDAQ:AKAO) opened at 22.64 on Wednesday. The stock’s market cap is $648.70 million. The stock has a 50 day moving average price of $21.99 and a 200-day moving average price of $11.44. Achaogen has a one year low of $2.59 and a one year high of $27.79.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/wedbush-reiterates-outperform-rating-for-achaogen-inc-akao.html
Achaogen (NASDAQ:AKAO) last issued its quarterly earnings results on Tuesday, March 14th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by $0.55. The business had revenue of $10.73 million for the quarter, compared to analysts’ expectations of $13.33 million. Achaogen had a negative return on equity of 143.44% and a negative net margin of 147.80%. The business’s revenue for the quarter was up 130.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.61) EPS. Equities research analysts expect that Achaogen will post ($2.25) earnings per share for the current fiscal year.
Your IP Address:
A number of institutional investors have recently modified their holdings of the company. FNY Partners Fund LP acquired a new position in shares of Achaogen during the fourth quarter worth about $158,000. State Street Corp purchased a new position in shares of Achaogen during the fourth quarter worth approximately $242,000. Ellington Management Group LLC purchased a new position in shares of Achaogen during the fourth quarter worth approximately $391,000. Redmile Group LLC purchased a new position in shares of Achaogen during the third quarter worth approximately $155,000. Finally, Hatteras Funds LP purchased a new position in shares of Achaogen during the fourth quarter worth approximately $488,000. Institutional investors own 44.47% of the company’s stock.
Achaogen Company Profile
Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.